Ferumoxytol did enhance CD86 expression and TNF-α production and downregulated CD206 with decreased IL-10, while our nanoparticles HA-man@Fe3O4 outperformed it in macrophage repolarizing with the same amount of iron, suggesting our nanoadjuvant might be efficient in cancer vaccine treatment with HA and mannose dual modification. The gene discussed is CD86; the disease is cancer.